Selective inhibition of cell proliferation by vav antisense olig

Details Selective inhibition of cell proliferation by vav antisense olig Selective inhibition of cell proliferation by vav antisense olig

1993-11-12

1997-03-18

Rories, Charles C. P.

Chemistry: molecular biology and microbiology

Treatment of micro-organisms or enzymes with electrical or...

Modification of viruses

435 6, 435 911, 435 913, 435 9133, 435 914, 4353201, 435375, 514 44, 536 231, 536 241, 536 243, 536 2431, 536 2433, 536 245, 536 251, 536 253, 536 2432, C12N 510, C12N 1585, C07H 2100, C12Q 168

Patent

active

056122128

ABSTRACT:
Antisense oligonucleotides specific for the vav proto-oncogene inhibit the proliferation of malignant, but not normal, myeloid cells. The oligonucleotides are therefore useful in the treatment of leukemias, in particular, as bone marrow purging agents. The vav antisense oligonucleotides also selectively inhibit the formation of erythroid cell colonies without effect on megakaryocyte and granulocyte/macrophage colony formation. The oligonucleotides are therefore useful in treating disorders characterized by an elevated hematocrit due to overproduction of erythrocytes.

REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5225326 (1993-07-01), Bresser et al.
Katzav et al., "vav, A Novel Human Oncogene Derived from a Locus Ubiquitously Expressed in Hematopoietic Cells", The Embo Journal, 8, 2283-2290 (1989).
Coppola et al., "Mechanism of Activationof the vav Protooncogene", Cell Growth & Differentiation 2, 95-105 (Feb. 1991).
Katzav et al., "Loss of the Amino-Terminal Helix-Loop-Helix Domain of the vav Proto-Oncogene . . . " Molecular and Cellular Biology 11, No. 4, pp. 1912-1920 (Apr. 1991).
Hu et al., "Vav: A Potential Link between Tyrosine Kinases and Ras-like . . . " BioEssays 15, No. 3, pp. 179-182 (Mar. 1993).
Bustelo et al., "Developmental Expression of the vav Protooncogene", Cell Growth & Differentiation 4, 297-308 (Apr. 1993).
Zhang, R., et al. PNAS, vol. 91 (Dec. 1994) pp. 12755-12759.
E. Uhlmann et al. Chemical Reviews, vol. 90, #4 (Jun. '90) pp. 543-584.
P. Westermann et al. Biochem. Biomed. Ama, vol. 48 ('89) pp. 85-93.
B. Tseng et al. Cancer Gene Therapy, vol. 1 #1 (Mar. 1994) pp. 65-71.
C. Stein et al. Science, vol. 261 (20 Aug. 1993) pp. 1004-1012.
R. Weiss Science News, vol. 139 (Feb. 16, 1991) pp. 108-109.
W. James, Antiviral Chem. & Chemotherapy, vol. 2 #4 ('91) pp. 191-214.
E. McCulloch et al. Blood Cells, vol. 7 ('81) 63-77.
J. Curtis et al. J. Clin. Oncology, vol. 2 #4 (Apr. 1984) pp. 253-259.
R. Mulligan Science, vol. 260 (14 May 1993) pp. 926-932.
E. Wicksman The Faseb Journal, vol. 5 #5 (Mar. 15, 1991) p. A1443.
J. Adams et al. Oncogene, vol. 7 ('92) pp. 611-618.
D. Merrola et al. Biochem Biophys. Res. Comm., vol. 147 #1 ('87) pp. 288-294.
J. Wermur, Chem Rev. in Biochem. & Mol. Biol., vol. 26 (3/4) ('91) 227-59.
Y. Rojanasak, Adv. Dwg Reliv. Rev., vol. 18 ('96) 115-31.

Affiliated with

Also associated with

Rating

Selective inhibition of cell proliferation by vav antisense olig does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective inhibition of cell proliferation by vav antisense olig, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective inhibition of cell proliferation by vav antisense olig will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1705531